The global credit crisis ensnared the pharmaceutical industry when Bristol-Myers Squibb revealed a $275m charge to write down illiquid securities with exposure to subprime mortgages. Read full article below.
The global credit crisis ensnared the pharmaceutical industry when Bristol-Myers Squibb revealed a $275m charge to write down illiquid securities with exposure to subprime mortgages. Read full article below.
